読み込み中
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
通常取引
$1.79
−$0.04 · -2.19%
日中の時刻はETです。市場データは遅延する場合があります。
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
日中レンジ
現在 $1.79
52週レンジ
現在 $1.79
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
43
適正価値
センチメント
56
まちまち
リスク
89
極めて高いリスク
モメンタム
20
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
日中レンジ
現在 $1.79
52週レンジ
現在 $1.79
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7000万 USD | — | — | — | — |
| 売上原価 | 32.5万 USD | — | 43.7万 USD | — | — |
| 粗利益 | 6967.5万 USD | — | −43.7万 USD | — | — |
| 研究開発 | 3355.8万 USD | 5131.2万 USD | 5891.3万 USD | 6443.7万 USD | 9682.9万 USD |
| 販売・一般管理 | 1657.2万 USD | 2746.9万 USD | 2711万 USD | 2839.1万 USD | 3004.3万 USD |
| 営業費用 | 4980.5万 USD | 7878.1万 USD | 8602.3万 USD | 9282.8万 USD | 1.27億 USD |
| 受取利息 | 406.1万 USD | 218.2万 USD | 192.4万 USD | 203.1万 USD | 346.4万 USD |
| 減価償却費と償却費 | 32.5万 USD | 34.3万 USD | 43.7万 USD | 50.8万 USD | 20.5万 USD |
| 営業利益 | 1987万 USD | −7878.1万 USD | −8646万 USD | −9282.8万 USD | −1.27億 USD |
| 純利益 | 2236.7万 USD | −6967.6万 USD | −8244.2万 USD | −9116.9万 USD | −1.26億 USD |
会社概要が更新されました 2026年10月8日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$11.83
上昇余地（560.89%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI326.81万0.00%2.3兆 USD0.03%$379.42-0.42%
iShares Russell 2000 ETFIWM225.57万0.00%785.63億 USD0.19%$275.06-0.95%
Fidelity Enhanced Small Cap ETFFESM112.41万0.02%64.1億 USD0.28%$44.82-0.88%
Vanguard Extended Market ETFVXF107.36万0.00%954億 USD0.05%$231.52-0.84%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV97.36万0.00%266.88億 USD0.33%$37.745-0.13%
iShares U.S. Small-Cap Equity Factor ETFSMLF91.63万0.02%41.62億 USD0.15%$84.055-0.68%
iShares Biotechnology ETFIBB68.04万0.01%104.01億 USD0.44%$197.02-3.11%
Vanguard Russell 2000 ETFVTWO57.18万0.00%180億 USD0.06%$111.09-1.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFU.S. Small Cap Value Portfolio ETF Class SharesDFSViShares U.S. Small-Cap Equity Factor ETFSMLFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
